7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions

7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions

Pharmacodynamics defines what a drug does to the body, exploring the biochemical, physiological, and molecular mechanisms of drug action. Anaesthesia relies on the reversible modulation of membrane-bound macromolecular receptors, including ligand-gated ion channels and G-protein coupled receptors, to induce hypnosis, analgesia, amnesia, and neuromuscular blockade.

---

1. Quantitative Receptor Theory and Ligand Efficacy

Receptors are specialized cellular proteins designed to bind endogenous chemical messengers and transduce conformational changes into intracellular responses. The interaction between a ligand ($L$) and its receptor ($R$) is conventionally modeled as a reversible bimolecular equilibrium: $[L] + [R] \underset{k_{\text{off}}}{\overset{k_{\text{on}}}{\rightleftharpoons}} [LR] \longrightarrow \text{Biological Effect}$

The dissociation constant ($K_D = \frac{k_{\text{off}}}{k_{\text{on}}}$) represents the ligand concentration at which 50% of the total receptor population is occupied at equilibrium. A lower $K_D$ denotes a higher binding affinity.

Conformational State Transitions:

         Inactive State (R) <=========> Active State (R*)
                  ^                               ^
                  |                               |
        Inverse Agonists (alpha < 0)       Full Agonists (alpha = 1.0)
        Stabilize R                        Stabilize R*

        Neutral Antagonists (alpha = 0): Bind R and R* with equal affinity,
        blocking agonist binding without altering baseline equilibrium.

Classification of Ligands by Intrinsic Efficacy ($\alpha$)

• Full Agonist ($\alpha = 1.0$): Binds selectively to the active receptor state ($R^*$), shifting the conformational equilibrium to elicit the maximum possible tissue response (e.g., morphine, fentanyl at $\mu$-opioid receptors; acetylcholine at nicotinic receptors).
• Partial Agonist ($0 < \alpha < 1.0$): Has intermediate affinity for both $R$ and $R^*$, stabilizing both conformations. Even at 100% receptor occupancy, it cannot elicit the maximal biological effect produced by a full agonist (e.g., buprenorphine at $\mu$-receptors). Clinical implication: When co-administered with a full agonist, a partial agonist displaces the full agonist from receptor sites, acting as a competitive antagonist and precipitating acute withdrawal or reversing deep analgesia.
• Neutral Antagonist ($\alpha = 0$): Binds with equal affinity to both inactive ($R$) and active ($R^*$) states without altering baseline equilibrium. It produces no biological effect on its own but competitively prevents agonist binding (e.g., vecuronium, rocuronium at nicotinic acetylcholine receptors; flumazenil at $GABA_A$ receptors).
• Inverse Agonist ($\alpha < 0$): Binds preferentially to the inactive receptor state ($R$), shifting equilibrium away from $R^*$. In receptors exhibiting spontaneous, baseline constitutive activity in the absence of any ligand, an inverse agonist suppresses this baseline signaling (e.g., $\beta$-carbolines at $GABA_A$ receptors; naloxone under conditions of upregulated constitutive $\mu$-receptor activity).

Antagonist Mechanisms: Competitive vs Non-Competitive

• Competitive (Surmountable) Antagonists: Reversibly bind to the same active (orthosteric) site as the endogenous agonist. Agonist and antagonist compete directly for the site. Higher concentrations of agonist can displace the antagonist, restoring the full maximal response ($E_{\max}$). This produces a parallel rightward shift in the agonist dose-response curve without altering $E_{\max}$. Examples include non-depolarizing neuromuscular blockers (rocuronium reversed by increased acetylcholine via neostigmine) and naloxone reversing morphine.
• Non-Competitive (Insurmountable) Antagonists: Bind irreversibly to the orthosteric site via covalent bonds, or bind reversibly to a separate allosteric site, altering receptor conformation so that agonist binding cannot activate the receptor. Increasing agonist concentration cannot overcome the blockade. This produces a depressed maximal response ($E_{\max}$), with or without a rightward shift. Examples include phenoxybenzamine at $\alpha$-adrenergic receptors and ketamine at NMDA receptors.

---

2. Dose-Response Dynamics: Potency, Efficacy, and Slope

Plotting biological response against the logarithm of drug concentration yields a characteristic symmetrical sigmoidal graded dose-response curve, described by the Hill equation: $E = \frac{E_{\max} \times [C]^n}{EC_{50}^n + [C]^n}$ where $E$ is observed effect, $E_{\max}$ is maximal efficacy, $EC_{50}$ is the concentration producing 50% of $E_{\max}$, and $n$ is the Hill coefficient (slope factor).

Effect (%)
100|                  Drug A (Potent, Emax 100%)
   |                 /|       Drug B (Less potent, Emax 100%)
 80|                / |      /|
   |               /  |     / |       Drug C (Partial agonist, Emax 50%)
 50|--------------*   |    *  |      /|
   |             /|   |   /|  |     *-|--------------------
 20|            / |   |  / |  |    /| |
   |           /  |   | /  |  |   / | |
  0+----------+---+---++---+--+--+--+-+------------------------>
             0.1  1   10  100   1000   Log Concentration (mg/L)

Key Metrics of the Dose-Response Curve

1. Potency ($EC_{50}$ or $ED_{50}$): The dose or concentration required to elicit 50% of the drug's maximal effect. Potency is reflected by the horizontal position of the curve along the x-axis. A curve shifted to the left denotes higher potency. For example, sufentanil ($ED_{50} \approx 0.1\ \mu\text{g/kg}$) is ~10 times more potent than fentanyl ($ED_{50} \approx 1\ \mu\text{g/kg}$) and ~1000 times more potent than morphine ($ED_{50} \approx 100\ \mu\text{g/kg}$). Importantly, potency does not indicate clinical superiority—only the mass of drug required.
2. Efficacy ($E_{\max}$): The maximum therapeutic response achievable by increasing drug dose, reflected by the upper plateau (vertical asymptote) of the curve along the y-axis. Full agonists share the same $E_{\max}$, whereas partial agonists possess a lower $E_{\max}$.
3. Slope ($n$): The steepness of the linear portion of the curve reflects the stoichiometry of receptor binding. A steep slope indicates that a small dose increment produces a dramatic transition from sub-therapeutic effect to complete receptor saturation or toxicity. Potent volatile anaesthetics and neuromuscular blockers have exceptionally steep slopes, requiring precise concentration titration. A shallow slope indicates a wider margin of titration between initial response and maximal effect.
4. Therapeutic Index ($TI$) and Margin of Safety: $TI = \frac{TD_{50}}{ED_{50}} \quad \text{or} \quad \frac{LD_{50}}{ED_{50}}$ $\text{Margin of Safety (MOS)} = \frac{LD_1 - ED_{99}}{ED_{99}} \times 100\%$ Most anaesthetic drugs (propofol, volatile agents) have notoriously low therapeutic indices ($TI \approx 2 - 4$), meaning toxic doses are only two to four times higher than effective anaesthetic doses, mandating continuous cardiovascular and respiratory vigilance.

---

3. Signal Transduction: G-Protein Coupled Receptors (GPCRs)

G-protein coupled receptors (GPCRs, 7-transmembrane heptahelical receptors) represent the largest superfamily of cell-surface signaling proteins. Agonist binding induces a conformational change that catalyzes the exchange of GDP for GTP on the heterotrimeric G-protein $\alpha$ subunit, causing dissociation of $G_\alpha$-GTP from the $G_{\beta\gamma}$ dimer to activate downstream effector cascades.

---

4. Ligand-Gated Ion Channels (Ionotropic Receptors) in Anaesthesia

Ionotropic receptors are multimeric membrane-spanning channel complexes that open directly in response to ligand binding, facilitating rapid millisecond-scale ionic flux.

                  GABA_A Receptor Pentamer (Top-Down View)

                                  alpha1
                                /        \
                          beta2            gamma2
                            |     [Cl-]      |
                            |     Pore       |
                          beta2            alpha1
                                \        /
                                  beta2 / ...

  Binding Sites:
  - GABA: alpha / beta interface
  - Benzodiazepines: alpha / gamma interface (requires alpha1, 2, 3, 5)
  - Propofol / Etomidate: beta subunit transmembrane cavities (beta2, beta3)
  - Barbiturates: allosteric transmembrane sites (direct Cl- pore opening at high doses)

The $GABA_A$ Receptor Complex

The $GABA_A$ receptor is the primary inhibitory neurotransmitter receptor in the mammalian brain. It is a heteropentameric chloride-selective channel assembled from 19 known subunits ($\alpha_{1-6}, \beta_{1-3}, \gamma_{1-3}, \delta, \epsilon, \pi, \theta, \rho_{1-3}$). The classic postsynaptic receptor configuration consists of two $\alpha$, two $\beta$, and one $\gamma$ subunit ($2\alpha_1, 2\beta_2, 1\gamma_2$):

• GABA Binding Site: Endogenous GABA binds at the two extracellular interfaces between $\alpha$ and $\beta$ subunits. Binding triggers channel opening, driving chloride ($Cl^-$) influx down its electrochemical gradient. This hyperpolarizes the postsynaptic neuronal membrane, moving resting potential further from threshold and suppressing action potential generation.
• Propofol and Etomidate: Bind to distinct, overlapping allosteric cavities within the transmembrane domains of the $\beta$ subunits (specifically $\beta_2$ and $\beta_3$ at methionine/asparagine residues such as $\beta_3\text{N}265$). They enhance GABA affinity, markedly prolonging the open-state deactivation time of the chloride channel.
• Benzodiazepines: Bind to a specific extracellular allosteric pocket at the $\alpha$ and $\gamma$ interface (requiring $\alpha_1, \alpha_2, \alpha_3,$ or $\alpha_5$ combined with $\gamma_2$). Benzodiazepines do not open the channel directly; they act as positive allosteric modulators that increase the frequency of channel opening bursts in the presence of GABA without altering single-channel conductance or open time. Reversible with flumazenil.
• Barbiturates: Bind distinct allosteric transmembrane sites. At low concentrations, they prolong the duration of open channel bursts. At high concentrations, barbiturates directly open the chloride pore in the total absence of GABA (direct channel agonism), accounting for their narrow therapeutic window and profound central nervous system depression.

The NMDA (N-Methyl-D-Aspartate) Receptor Complex

The NMDA receptor is a tetrameric, ligand-gated cation channel ($2 GluN1 + 2 GluN2$ subunits) mediating excitatory glutamatergic neurotransmission in the brain and dorsal horn of the spinal cord:

• Dual Co-Agonist Requirement: Activation mandates the simultaneous binding of both L-glutamate (on $GluN2$) and glycine or D-serine (on $GluN1$).
• Voltage-Dependent Magnesium Block: At resting membrane potentials ($-70\text{ mV}$), the central channel pore is occluded by an extracellular magnesium ($Mg^{2+}$) ion. Only when adjacent AMPA receptors depolarize the membrane is the $Mg^{2+}$ ion electrostatically expelled from the pore, permitting substantial calcium ($Ca^{2+}$) and sodium ($Na^+$) influx and potassium ($K^+$) efflux.
• Anaesthetic Blockade: Ketamine, nitrous oxide ($N_2O$), and xenon act as uncompetitive/non-competitive open-channel blockers. Ketamine binds inside the channel pore to the phencyclidine (PCP) site when the channel is opened, physically occluding $Ca^{2+}$ transit. This inhibits dorsal horn wind-up (central sensitization) and produces dissociative anaesthesia.

Nicotinic Acetylcholine Receptors (nAChR): Adult Junctional vs Fetal Extrajunctional

The nicotinic acetylcholine receptor is a pentameric ligand-gated cation channel situated at the neuromuscular junction:

• Adult Junctional nAChR: Composed of $2\alpha_1, 1\beta_1, 1\delta, 1\epsilon$ subunits arranged around a central pore. Channel opening requires simultaneous binding of two acetylcholine molecules to both $\alpha_1$ subunits, driving $Na^+$ and $Ca^{2+}$ influx and generating an endplate potential (EPP).
• Fetal (Extrajunctional) nAChR: Features a $\gamma$ subunit in place of the adult $\epsilon$ subunit ($2\alpha_1, 1\beta_1, 1\delta, 1\gamma$). Fetal receptors possess a lower single-channel conductance but a significantly prolonged mean channel open time (2- to 10-fold longer than adult receptors).

Adult Postsynaptic nAChR               Fetal / Extrajunctional nAChR
- Structure: 2 alpha1, 1 beta1,        - Structure: 2 alpha1, 1 beta1,
             1 delta, 1 epsilon                     1 delta, 1 gamma (gamma replaces epsilon)
- Location: Motor endplate crests      - Location: Proliferates across entire sarcolemma
- Conductance: High, short open time   - Conductance: Lower, prolonged channel open time
- Denervation response: Stable         - Succinylcholine triggers massive K+ efflux

Clinical Trap: Succinylcholine-Induced Hyperkalemia: Following upper or lower motor neuron denervation (stroke, spinal cord transection, ALS), prolonged muscular disuse / immobilization (ICU myopathy), major burn injury, severe intra-abdominal sepsis, or direct muscle trauma, fetal ($2\alpha_1, 1\beta_1, 1\delta, 1\gamma$) and $\alpha_7$ homopentameric receptors proliferate across the entire sarcolemmal surface away from the motor endplate. When succinylcholine binds to these upregulated extrajunctional receptors, their prolonged open time causes massive, uncontrolled systemic potassium ($K^+$) efflux. Serum potassium can surge by 3-7 mmol/L within minutes, provoking peaked T waves, ventricular fibrillation, and refractory cardiac arrest. Succinylcholine is strictly contraindicated starting 24-48 hours after denervation, burns, or severe trauma, and throughout the duration of critical illness immobilization.

---

5. Pharmacodynamic Drug Interactions: Additive, Synergistic, and Antagonistic

When two or more neuroactive drugs are co-administered, their combined clinical effect may be classified mathematically via isobolographic analysis:

1. Additive Interaction ($1 + 1 = 2$): The combined effect equals the simple algebraic summation of the individual drugs' actions acting through independent or identical mechanisms. Plotted on an isobologram, the line connecting the $ED_{50}$ of Drug A and Drug B is a straight diagonal line. For example, combining volatile anaesthetics (0.5 MAC sevoflurane + 0.5 MAC nitrous oxide = 1.0 MAC total depth) exhibits strictly additive immobility.
2. Synergistic (Supra-Additive) Interaction ($1 + 1 > 2$): The combined clinical effect is significantly greater than the sum of their individual effects, yielding a concave (inward-bowed) isobologram curve. Classical examples include:
   • Benzodiazepines + Opioids (e.g., Midazolam + Fentanyl): Midazolam facilitates GABAergic transmission while opioids activate $\mu$-opioid $G_i$ pathways. Together, they demonstrate marked synergism in hypnosis and sedation. Most critically, they produce catastrophic synergistic depression of hypoxic and hypercapnic ventilatory drives, flattening the slope of the ventilatory response curve to carbon dioxide far beyond either drug alone.
   • Propofol + Opioids: The hypnotic requirement ($C_{e50}$ of propofol for loss of consciousness) drops by up to 50-70% in the presence of therapeutic concentrations of remifentanil or fentanyl.
3. Antagonistic Interaction ($1 + 1 < 1$): The combined effect is less than would be expected from either drug alone. In anaesthesia, antagonism is frequently leveraged for reversal:
   • Pharmacological Antagonism: Naloxone competitively antagonizes $\mu, \kappa, \delta$ opioid receptors; flumazenil competitively antagonizes the benzodiazepine site on $GABA_A$ receptors.
   • Chemical Antagonism (Chemo-encapsulation): Sugammadex (a modified $\gamma$-cyclodextrin) features a lipophilic core and a hydrophilic outer shell with negatively charged carboxyl groups. It encapsulates rocuronium and vecuronium in plasma with a 1:1 molecular stoichiometry ($K_D \approx 10^{-7}\text{ M}$), lowering free plasma relaxant concentration and driving drug off the neuromuscular junction down a concentration gradient.

---

6. Cytochrome P450 Enzyme Induction and Inhibition

Hepatic drug metabolism comprises Phase I reactions (oxidation, reduction, and hydrolysis catalyzed predominantly by the microsomal Cytochrome P450 [CYP] monooxygenase enzyme superfamily) and Phase II reactions (conjugation with glucuronide, sulfate, acetate, or glutathione to enhance water solubility for renal excretion).

Phase I Metabolism (CYP Enzymes: 3A4, 2D6, 2B6, 2E1, 1A2)
-------------------------------------------------------------------------
Enzyme Inducers (Increase CYP synthesis)   Enzyme Inhibitors (Block CYP activity)
- Onset: Slow (days to weeks)              - Onset: Immediate (hours)
- Effect: Lower drug levels, failure       - Effect: Elevated drug levels, toxicity
- Examples:                                - Examples:
  * Rifampin                                 * Ketoconazole / Itraconazole
  * Carbamazepine                            * Erythromycin / Clarithromycin
  * Phenytoin / Phenobarbital                * Cimetidine
  * St. John's wort                          * Ciprofloxacin
  * Chronic alcohol abuse                    * Grapefruit juice (intestinal CYP3A4)
  * Cigarette smoke (CYP1A2)                 * Acute alcohol intoxication

Clinical Implications in Anaesthesia

• CYP3A4 metabolizes ~50% of all pharmaceuticals, including midazolam, fentanyl, alfentanil and sufentanil (rocuronium, by contrast, is cleared largely unchanged in bile and urine). Co-administration of a potent CYP3A4 inhibitor (e.g., erythromycin, ketoconazole, diltiazem) impairs midazolam and fentanyl clearance, causing prolonged post-operative sedation and delayed emergence.
• CYP2B6 metabolizes propofol and ketamine. Genetic polymorphisms or enzyme inhibition alter clearance rates and recovery times.
• CYP2E1 metabolizes volatile inhalational anaesthetics (sevoflurane, isoflurane, and classically halothane). Chronic ethanol abuse induces CYP2E1, accelerating volatile anaesthetic biotransformation and potentially augmenting toxic metabolite formation.